|
[1]
|
Pan Y, Wang L, Feng ZM, Xu H, Shen Y, Zhang DT, et al. Characterisation of SARS-CoV-2 variants in Beijing during 2022: an epidemiological and phylogenetic analysis. Lancet 2023;401(10377):664 − 72. http://dx.doi.org/10.1016/S0140-6736(23)00129-0CrossRef
|
|
[2]
|
Chinese Center for Disease Control and Prevention. COVID-19 clinical and surveillance data — December 9, 2022 to April 27, 2023, China. China CDC Wkly 2023. https://weekly.chinacdc.cn/fileCCDCW/cms/news/info/upload//e712e241-fbcb-426b-9ac8-551ce6fd7ccc.pdf.https://weekly.chinacdc.cn/fileCCDCW/cms/news/info/upload//e712e241-fbcb-426b-9ac8-551ce6fd7ccc.pdf |
|
[3]
|
Cao YL, Jian FC, Wang J, Yu YL, Song WL, Yisimayi A, et al. Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution. Nature 2023;614(7948):521 − 9. http://dx.doi.org/10.1038/s41586-022-05644-7CrossRef
|
|
[4]
|
Li DD, Duan MR, Wang X, Gao PY, Zhao X, Xu K, et al. Neutralization of BQ. 1, BQ.1.1, and XBB with RBD-dimer vaccines. N Engl J Med 2023;388(12):1142 − 5. http://dx.doi.org/10.1056/NEJMc2216233CrossRef
|